56 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
cease to be classified as a PFIC, the U.S. Holder would not be required to take into account any latent gain or loss in the manner described above … and any realized gain or loss would be classified as a capital gain or loss. A mark-to-market election will not apply to our common shares for any taxable
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
and thereafter as capital loss. If, after having been a PFIC for one or more taxable years, we cease to be classified as a PFIC, the U.S. Holder would … not be required to take into account any latent gain or loss in the manner described above and any realized gain or loss would be classified as a capital
424B5
hd3cyqj
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
f3o9c
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
4ytmreg u9wv6
1 Mar 22
Prospectus supplement for primary offering
5:12pm
424B5
2eu6e00uf 1hgnsnhj
6 Oct 21
Prospectus supplement for primary offering
5:05pm
424B5
tknlsm8
4 Oct 21
Prospectus supplement for primary offering
5:27pm
424B5
lv0af2fe2
9 Mar 21
Prospectus supplement for primary offering
5:26pm